Changeflow GovPing Healthcare Letter from USPTO to FDA CDER Regarding Patent ...
Routine Notice Added Final

Letter from USPTO to FDA CDER Regarding Patent Matters

Favicon for www.regulations.gov Regs.gov: Food and Drug Administration
Detected
Email

Summary

The USPTO sent correspondence to FDA's Center for Drug Evaluation and Research on April 9 regarding patent-related matters. The document is filed under docket FDA-2026-E-3821-0001 and is available only as an attachment PDF on regulations.gov.

View original document View source feed page

What changed

The USPTO issued a letter to FDA CDER regarding patent matters, filed as an attachment to docket FDA-2026-E-3821-0001. The full document content is not accessible in the public view but is available for download as a PDF attachment.

Affected parties including pharmaceutical companies, patent applicants, and regulatory affairs professionals should monitor this docket for additional related filings, FDA responses, or supporting documentation that may clarify the subject matter of this inter-agency communication.

What to do next

  1. Monitor regulations.gov for related FDA CDER responses
  2. Review attachment PDF for substantive content

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

There are no documents available to view or download

Attachments 1

Letter from U. S. Patent and Trademark Office to FDA CDER

More Information
- Author(s) CDER
Download

Related changes

Favicon for www.regulations.gov USPTO Letter to FDA CDER Regarding Patent Matters
Routine Apr 10, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.regulations.gov USPTO Letter to FDA CDER on Patent Matters, Apr 8
Routine Apr 10, 2026 • Regs.gov: Food and Drug Administration • Healthcare
Favicon for www.regulations.gov USPTO Letter to FDA CDER on Patent Matters
Routine Apr 10, 2026 • Regs.gov: Food and Drug Administration • Healthcare

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

Source

Favicon for www.regulations.gov
Regs.gov: Food and Drug Administration regulations.gov/search?agencyIds=FDA&sortBy=postedDate&sortDirection=desc
Healthcare

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Press inquiries →

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FDA-2026-E-3821-0001
Docket
FDA-2026-E-3821-0001

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent correspondence Inter-agency communication
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Browse Categories

Agriculture & Food Safety 63 AI Regulation 3 Banking & Finance 292 Consumer Protection 44 Courts & Legal 360 Data Privacy & Cybersecurity 74 Defense & National Security 52 Education 20 Energy 101 Environment 85 Environmental Permits 1 Environmental Regulation 8 Financial Regulation 2 Government & Legislation 278 Healthcare 136 Housing 16 Immigration 9 Insurance 58 Labor & Employment 113 Legal 1 Legislative 1 Pharma & Drug Safety 104 Public Health 3 Securities & Markets 104 Securities Regulation 9 Tax 66 Telecom & Technology 47 Trade & Sanctions 136 Transportation 57

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!